Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

FHS
May 15, 2024
9:10 am

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.

African nations must take ownership of HIV response to reduce disease burden

Africa must take ownership of its HIV response, write Izukanji Sikazwe and Magda Robalo, co-chairs of the African-led HIV Control Working Group.

October 9, 2024

Texas Heart Institute receives $1.14 million grant to develop first-in-class drug to treat cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class

August 23, 2023

PFA devices are changing AFib treatment. The next wave could grow the market further.

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. A new technique for treating patients with

June 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.